Everyone knows how people with kidney disease go in, two or three times a week for kidney dialysis, that removes impurities from their blood, right?

Well, they are close to developing such techniques that can remove a 58% of AIDS and Hep C viruses from the bloodstream in TWO hours.

Problem is the virus replicates like crazy. So this would be an ongoing therapy, and probably no easier to tolerate than kidney dialysis.

Nevvertheless, it is a potetnial treatment.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

LA JOLLA, Calif.--(BUSINESS WIRE)--Jan. 31, 2003--
Aethlon Medical Inc. (OTCBB:AEMD) today announced that initial
pre-clinical human blood studies of the company's new
HCV-Hemopurifier(TM) have documented a consistent ability to remove
58 percent of Hepatitis-C virus (HCV) from infected blood in two
hours.

The data was presented at the "International Conference on Dialysis
V" which ends today in Miami, Florida. The data compares favorably
with Aethlon's lead product AEMD-45, which is a HIV treatment
Hemopurifier(TM) that is able to remove 55 percent of HIV from
human blood in three hours and in excess of 85 percent in 12 hours.

"This data helps substantiate the clinical expectation that our
Hemopurifier(TM) treatment platform can be effective for numerous
disease states," said James A. Joyce, Chairman and CEO. "Our data
becomes especially important when considering the magnitude of HIV
and HCV infections and the reality that both viruses can mutate to
defeat current drug therapies."

According to the Centers for Disease Control (CDC), over 200 million people
worldwide are
infected with the Hepatitis-C (HCV) virus. In the United States,
HCV has become the most common chronic, blood-borne disease with
nearly 4 million infected. Chronic and progressive Hepatitis C,
which represents 80-90 percent of all cases, has significant
morbidity and mortality rates, and is the leading cause of liver
disease and transplantation.

Richard Tullis, Ph.D., chief scientific officer at Aethlon stated,
"This is a significant advance in Aethlon's virus treatment
platform. The possibility now exists that we will be able to
deliver a medical device that can simultaneously treat both HIV
and HCV infections, a factor that could be crucial for the large
population of patients that are infected with both diseases."

About Aethlon Medical

Aethlon Medical develops therapeutic devices that treat HIV/AIDS,
Hepatitis-C (HCV) and other infectious diseases. In pre-clinical
testing, Aethlon has published that AEMD-45, its lead product for
treating HIV, is able to remove 55 percent of HIV from infected
human blood in three hours and in excess of 85 percent in 12 hours.
Aethlon has also documented that AEMD-45 removes up to 90 percent
of toxic viral proteins that deplete immune cells during the
equivalent of a one-hour treatment. The AEMD-45 therapeutic device,
like all product offerings from Aethlon Medical, is developed from
an expansive platform technology known as the Hemopurifier(TM),
which employs a proprietary method to increase the capability of
FDA cleared artificial kidneys (dialysis cartridges) to remove
targeted intoxicants from the blood. In the case of AEMD-45,
dialysis cartridges are modified to mimic the immune system's
response to clear infectious virus from circulation before healthy
cells are infected. AEMD-45 is designed to fill the urgent need
for new treatments that are effective in reducing viral load,
decrease the likelihood of treatment resistance and treat without
the toxic side-effects associated with AIDS drugs. For more
information, visit the company's Web site at www.AethlonMedical.com.

Certain of the statements herein may be forward-looking and
involve risks and uncertainties. Such forward-looking statements
involve assumptions, known and unknown risks, uncertainties and
other factors which may cause the actual results, performance or
achievements of Aethlon Medical Inc. to be materially different
from any future results, performance or achievements expressed or
implied by the forward-looking statements. Such potential risks
and uncertainties include, without limitation, the company's
ability to raise capital when needed, the company's ability to
complete the development of its planned products, the ability of
the company to obtain FDA and other regulatory approvals permitting
the sale of its products, the company's ability to manufacture its
products and provide its services, the impact of government
regulations, patent protection on the company's proprietary
technology, product liability exposure, uncertainty of market
acceptance, competition, technological change, and other risk
factors. In such instances, actual results could differ materially
as a result of a variety of factors, including the risks
associated with the effect of changing economic conditions and
other risk factors detailed in the company's Securities and
Exchange Commission filings.

CONTACT:

Aethlon Medical Inc.

James A. Joyce, 858/456-5777

SOURCE: Aethlon Medical Inc.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

All My Love,
Menolly